Caris Life Sciences, Inc. (CAI) stock
CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30104% above fair value
$19.94−1.06 (-5.05%)
Close on Nov 17, 2026Market cap $5.63BP/E –Yield –
Caris Life Sciences r&d expenses
Research and development expenses are spending on new products and technology.
Caris Life Sciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $129.36M, up 33.6% year over year. For fiscal 2025 it was $101.58M, down 10.8% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $101.58M | -10.8% |
| FY2024 | Dec 31, 2024 | $113.92M | -2.5% |
| FY2023 | Dec 31, 2023 | $116.88M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $33.84M | +56.5% |
| Q2 FY2026 | Jun 30, 2026 | $32.36M | +29.2% |
| Q1 FY2026 | Mar 31, 2026 | $31.32M | +35.8% |
| Q4 FY2025 | Dec 31, 2025 | $31.85M | +17.5% |
| Q3 FY2025 | Sep 30, 2025 | $21.62M | -21.8% |
| Q2 FY2025 | Jun 30, 2025 | $25.05M | +1.0% |
| Q1 FY2025 | Mar 31, 2025 | $23.07M | – |
| Q4 FY2024 | Dec 31, 2024 | $27.11M | – |
| Q3 FY2024 | Sep 30, 2024 | $27.64M | – |
| Q2 FY2024 | Jun 30, 2024 | $24.79M | – |
See a number that looks wrong?